Prophylactic Treatment With Oral Deucrictibant Improves Hereditary Angioedema Disease Control and Health-Related Quality of Life

H. James Wedner[1], John Anderson[2], Hugo Chapdelaine[3], Markus Magerl[4,5], Michael E. Manning[6], Marc A. Riedl[7], Peng Lu[8], Emel Aygören-Pürsün[9]

[1]Washington University School of Medicine, Division of Allergy and Immunology, Department of Medicine, St. Louis, MO, USA; [2]AllerVie Health, Clinical Research Center of Alabama, Birmingham, AL, USA; [3]Université de Montréal, CHU de Montréal, Montréal, QC, Canada; [4]Charité – Universitätsmedizin Berlin, Institute of Allergology, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; [5]Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany; [6]Allergy, Asthma and Immunology Associates, Ltd., Scottsdale, AZ, USA; [7]University of California San Diego, Division of Allergy and Immunology, La Jolla, CA, USA; [8]Pharvaris Inc., Lexington, MA, USA; [9]University Hospital Frankfurt, Department for Children and Adolescents, Goethe University Frankfurt, Frankfurt, Germany

Introduction

- International hereditary angioedema (HAE) guidelines recommend that the goals of treatment are to achieve total disease control and to normalize patients' lives.[1]
- HAE negatively impacts functional and psychological domains of health-related quality of life (HRQoL).[2-6]
- Patients with well-controlled disease report lower disease burden, lower burden on daily activities, and greater HRQoL than patients with poorly controlled disease.[7]
- Despite the availability of approved therapies for HAE, an unmet need remains for additional prophylactic treatments combining injectable-like efficacy, a well-tolerated profile, and ease of administration.[8-11]
- Deucrictibant is a selective, orally administered bradykinin B2 receptor antagonist under development for prophylactic and on-demand treatment of HAE attacks.[12-17]

Methods

- CHAPTER-1 (NCT05047185)[17*] is a two-part, Phase 2 study evaluating the efficacy, safety, and tolerability of deucrictibant for long-term prophylaxis against angioedema attacks in HAE-1/2.
- Eligible participants were ≥18 and ≤75 years of age, diagnosed with HAE-1/2, were not receiving other prophylactic treatments at the time of screening, and had experienced ≥3 attacks within the past 3 consecutive months prior to screening or ≥2 attacks during screening (up to 8 weeks).
- In placebo-controlled part 1, participants were randomized to receive 1 of 2 doses of double-blinded deucrictibant (20 mg/day or 40 mg/day) or placebo for 12 weeks of treatment (**Figure 1**).

Figure 1. Study design



IR, immediate release; OLE, open-label extension; R, randomization. RCT, randomized controlled trial. [a]Deucrictibant IR capsule, 10 mg twice daily. [b]Deucrictibant IR capsule, 20 mg twice daily.

- Deucrictibant immediate-release (IR) capsule was dosed twice per day as a proof-of-concept for the once-daily deucrictibant extended-release tablet, which is the intended formulation of deucrictibant for prophylactic HAE treatment.[18,19]
- Patient-reported outcomes (PROs) were assessed using pre-defined endpoints (**Table 1**).

Table 1. PRO endpoints

Disease control, HRQoL, and treatment satisfaction were assessed using pre-defined endpoints:	
Disease control	• Angioedema Control Test (AECT): 4-week recall version[20,21]
Health-related quality of life	• Angioedema QoL Questionnaire (AE-QoL)[22,23] • Patient Global Assessment of Change (PGA-Change)
Treatment satisfaction	• Treatment Satisfaction Questionnaire for Medication (TSQM) Version II[24]

HRQoL, health-related quality of life; PRO, patient-reported outcome; QoL, quality of life.

Results

- Results from the CHAPTER-1 randomized controlled trial (RCT) are reported here.
- Thirty-four participants were enrolled and randomized at sites in Canada, Europe, the United Kingdom, and the United States.
- Treatment with deucrictibant resulted in well-controlled HAE by week 4 and throughout treatment (**Figure 2**).
- A total of 90% of participants on deucrictibant showed well-controlled HAE at week 12 (**Figure 3**).

Figure 2. AECT: Well-controlled HAE by week 4 in deucrictibant-treated participants



AECT, Angioedema Control Test; HAE, hereditary angioedema; IR, immediate-release. N' = number of participants with AECT data at week 12. [a]Deucrictibant IR capsule, 10 mg twice daily. [b]Deucrictibant IR capsule, 20 mg twice daily.

Figure 3. AECT: 90% well-controlled at week 12 in deucrictibant-treated participants



AECT, Angioedema Control Test; IR, immediate-release; RCT, randomized controlled trial. N = number of participants randomized in each treatment group in the RCT. N' = number of participants with AECT data at week 12. [a]Deucrictibant IR capsule, 10 mg twice daily. [b]Deucrictibant IR capsule, 20 mg twice daily.

- The mean AE-QoL Total Score improved from baseline to week 12 by 19.0 and 25.9 points in participants receiving deucrictibant 20 mg/day and 40 mg/day, respectively, vs 11.9 points in the placebo group (**Figures 4 and 5**).
- The AE-QoL domains that showed the greatest improvement with deucrictibant treatment were "fear/shame" and "functioning" (**Figure 4**).

Figure 4. AE-QoL: HRQoL improvement across all domains



Figure 5. AE-QoL: Total Score improvement from baseline by week 4 and throughout treatment



AE-QoL, Angioedema Quality of Life Questionnaire; HRQoL, health-related quality of life; IR, immediate-release; Q, quartile; SD, standard deviation. N = number of randomized participants with AE-QoL data at baseline. N' = number of participants with AE-QoL data at week 12. [a]Deucrictibant IR capsule, 10 mg twice daily. [b]Deucrictibant IR capsule, 20 mg twice daily.

Results

- Deucrictibant treatment resulted in greater patient satisfaction with effectiveness (**Figure 6A**) and greater overall patient satisfaction (**Figure 6B**) vs placebo.

Figure 6. TSQM: Improvement in patient satisfaction in deucrictibant-treated participants



IR, immediate-release; TSQM, Treatment Satisfaction Questionnaire for Medication. N' = number of participants with TSQM results at week 12. [a]Deucrictibant IR capsule, 10 mg twice daily. [b]Deucrictibant IR capsule, 20 mg twice daily. [c]Dose frequency was twice daily using IR capsule; once daily tablet is the intended formulation for the Phase 3 trial.

Conclusions

- **The CHAPTER-1 Phase 2 trial provides encouraging results on the effects of prophylactic treatment with oral deucrictibant for 12 weeks on HAE control, HRQoL, and treatment satisfaction in people living with HAE.**
  - **Deucrictibant improved disease control from as early as week 4 vs placebo, with 90% of participants in the deucrictibant groups demonstrating well-controlled HAE at week 12.**
  - **Using AE-QoL, deucrictibant improved health-related quality of life from as early as week 4 and through treatment vs placebo, with greatest improvements in "functioning" and "fear/shame" domains.**
  - **Participants reported high levels of satisfaction with deucrictibant.**
- **Confirmation of these data in the planned Phase 3 study may provide further evidence on deucrictibant as a potential treatment to address existing unmet needs in HAE disease control and HRQoL.**
- **CHAPTER-1 OLE data showing maintained improvement in disease control and HRQoL through one year of deucrictibant treatment to be presented at upcoming scientific conferences.**

References

1. Maurer M, et al. *Allergy*. 2022;77:1961-90. **2.** Bork K, et al. *Allergy Asthma Clin Immunol*. 2021;17:40. **3.** Bygum A, et al. *Front Med*. 2017;4:212. **4.** Mendivil J, et al. *Orphanet J Rare Dis*. 2021;16:94. **5.** Chong-Neto HJ. *World Allergy Organ J*. 2023;16:100758. **6.** Lumry WR, et al. *Allergy Asthma Proc*. 2010;31(5):407-14. **7.** Grumach A, et al. *J Allergy Clin Immunol*. 2024;153(2)(suppl). Abstract AB92. **8.** Bouillet L, et al. *Allergy Asthma Proc*. 2022;43:406-12. **9.** Betschel SD, et al. *J Allergy Clin Immunol Pract*. 2023;11:2315-25. **10.** Center for Biologics Evaluation and Research. The voice of the patient – hereditary angioedema. US Food and Drug Administration; May 2018. Accessed September 27, 2024. https://www.fda.gov/media/113509/download; **11.** Covella B, et al. *Future Pharmacol*. 2024;4:41-53. **12.** https://clinicaltrials.gov/study/NCT04618211. Accessed September 27, 2024. **13.** Maurer M, et al. Presented at: AAAAI; February 24–27, 2023; San Antonio, TX, USA. **14.** https://www.clinicaltrials.gov/study/NCT05396105. Accessed September 27, 2024. **15.** https://clinicaltrials.gov/study/NCT06343779. Accessed September 27, 2024. **16.** Riedl MA, et al. Presented at: AAAAI; February 23–26; Washington, DC, USA. **17.** https://www.clinicaltrials.gov/study/NCT05047185. Accessed September 27, 2024. **18.** Groen K, et al. Presented at: ACAAI; November 10–14, 2022; Louisville, KY, USA. **19.** Petersen RS et al. Presented at: Bradykinin Symposium 2024; Sep 5–6, 2024; Berlin, Germany. **20.** Weller K, et al. *Allergy*. 2020;75(5):1165-77. **21.** Weller K, et al. *J Allergy Clin Immunol Pract*. 2020b;8(6):2050-57. **22.** Weller K, et al. *Allergy*. 2012;67:1289-98. **23.** Weller K, et al. *Allergy*. 2016;71:1203-9. **24.** Atkinson MJ, et al. *Value Health*. 2005;8(s1):S9-24.

This presentation includes data for an investigational product not yet approved by regulatory authorities.

COI: Grants/research support, honoraria or consultation fees, sponsored speaker bureau – **H.J.W.:** BioCryst, BioMarin, CSL Behring, Genentech, GSK, Takeda; **J.A.:** BioCryst, BioMarin, CSL Behring, Cycle Pharma, KalVista, Pharming, Pharvaris, Takeda; **H.C.:** AstraZeneca (Alexion), CSL Behring, KalVista, Merck, Novartis, Pharming, Pharvaris, Roche, Sanofi, Sobi, Takeda; **M.M.:** BioCryst, CSL Behring, Intellia, KalVista, Novartis, Octapharma, Pharming, Pharvaris, Takeda; **M.E.M.:** Allakos, Amgen, AstraZeneca, BioCryst, Blueprint, CSL Behring, Cycle Pharma, Genentech, GSK, KalVista, Merck, Novartis, Pharming, Pharvaris, Sanofi/Regeneron, Takeda; **M.A.R.:** Astria, BioCryst, BioMarin, CSL Behring, Cycle Pharma, Fresenius-Kabi, Grifols, Ionis, Ipsen, KalVista, Ono Pharma, Pfizer, Pharming, Pharvaris, RegenxBio, Sanofi/Regeneron, Takeda; **P.L.:** employee of Pharvaris, holds stocks in Pharvaris; **E.A-P.:** Astria, BioCryst, BioMarin, CSL Behring, Intellia, KalVista, Pharming, Pharvaris, Takeda.
Acknowledgments: Medical writing services were provided by Scott Salsman, PhD, on behalf of Two Labs Pharma Services.

*CHAPTER-1 is a Pharvaris-sponsored clinical trial. ClinicalTrials.gov Identifier: NCT05047185.